• Simcere Zaiming sold 30,000 NextCure common shares on Aug. 10, 2026 at $6.16.
• Beneficial ownership fell to 308,636 shares following the sale.
• Filing marked an exit from Section 16 reporting after the group dropped below a 10% stake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088156), on August 12, 2026, and is solely responsible for the information contained therein.